What is Si02?
SiO2 Material Science operates at the intersection of material science and biopharmaceutical packaging. The company's core innovation lies in its proprietary vyterial coating technology, which is protected by over 300 patents. This technology aims to provide the inertness and barrier properties of glass combined with the durability and flexibility of polymers. SiO2's product portfolio includes syringes, vials, and blood collection tubes, designed to address critical industry challenges such as silicone oil contamination, drug interactions, and product breakage. The company targets pharmaceutical and biotechnology firms seeking reliable and safe containment for life-saving medications, emphasizing sustainability and health in its offerings.
How much funding has Si02 raised?
Si02 has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Si02
PPP
Public-Private Partnership
What's next for Si02?
The recent major strategic investment signifies a pivotal moment for Si02, likely indicating a transition towards scaling its operations and expanding its market reach. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and strengthen its commercialization efforts. As Si02 continues to innovate in the high-stakes biopharmaceutical packaging market, its focus on patent-protected technology and addressing key industry pain points positions it for sustained growth and influence in ensuring the safe distribution of critical therapeutics.
See full Si02 company page
